DUBLIN--(BUSINESS WIRE)--The "Global Oncolytic Virus Therapy Market Outlook 2028" report has been added to ResearchAndMarkets.com's offering.
The market is anticipated to garner a revenue of around USD 1060 Million by the end of 2028, up from a revenue of close to USD 160 Million in the year 2019. The global oncolytic virus therapy market is estimated to grow with a CAGR of 27.29% over the forecast period, i.e., 2021 - 2028.
Factors such as the rapid advancements in healthcare sector, increasing healthcare expenditure, and the surge in cancer cases are expected to drive the market growth during the forecast period.
The global oncolytic virus therapy market is segmented by numerous segments which include segmentation by therapy type, virus type, indication, demography, end-user, and by region. Based on therapy type, the market is segmented into HSV-based oncolytic virus therapy, adenovirus-based oncolytic virus therapy, reovirus, poxviruses, Newcastle disease virus (NDV), and others.
Amongst these segments, the adenovirus-based oncolytic virus therapy segment held the highest market share of about 30% in 2019 and is further projected to grab a significant market share during the forecast period.
On the basis of region, the global oncolytic virus therapy market is segmented into North America, Europe, Asia Pacific, and the Rest of World, out of which, the market in North America registered the largest market revenue of close to USD 70 Million in 2019 and is further expected to touch USD 510 Million approximately by the end of 2028.
Some of the leading market players in the global oncolytic virus therapy market are
- Amgen Inc.
- Shanghai Sunway Biotech Co. Ltd.
- Oncolys BioPharma Inc.
- TILT Biotherapeutics Ltd.
- Oncorus Inc.
- Takara Bio Inc.
- Vyriad
- Transgene sa
- Lokon Pharma AB
- Pfizer Inc
Key Topics Covered:
1. Introduction
2. Assumptions and Acronyms
3. Research Methodology
4. Executive Summary - Global Oncolytic Virus Therapy Market (2019-2028)
5. Analysis of Market Dynamics
5.1. Growth drivers
5.2. Opportunities
5.3. Market Trends
5.4. Restraints
6. Regulatory & Standards Landscape
6.1. Manufacturing Standards & Compliances
6.2. Environmental Compliances
7. Analysis on the Mechanism of Oncolytic Virus Therapy
8. Recent Developments in Oncolytic Virus Therapy Market
9. Pipeline Analysis
9.1. Clinical Trial Outlook
10. Epidemiology Analysis
11. Oncolytic Virus Platforms Under Evaluation
11.1. Adenovirus
11.2. Herpes Simplex Virus
11.3. Maraba Virus
11.4. Measles
11.5. Newcastle Disease Virus
11.6. Others
12. Impact of COVID-19 on the Oncolytic Virus Therapy Market
12.1. Impact of COVID-19 on the Overall Healthcare Sector
12.2. Impact on Demand
12.3. Impact on the Cancer Treatment
12.4. Impact on the Manufacturers
12.5. Impact on the Research & Development Activities
12.6. Impact on the Product Pipeline
12.7. Impact on the Key Market Players
12.8. Impact on the New Entrants in the Market
12.9. Impact on the Pricing
12.10. Market Impact Analysis in 2020 (quarter wise) w.r.t COVID-19 Pandemic (USD Million)
13. Analysis on the Oncolytic Virus Therapy
14. Analysis on the Oncolytic Virus Therapy Cost, USD
15. End-User Analysis
16. Competitive Structure (Both Marketed and Pipeline Drugs)
16.1. Market Share Analysis, 2020
16.2. Profiled Companies
16.2.1. Amgen Inc.
16.2.2. Shanghai Sunway Biotech Co., Ltd.
16.2.3. Oncolys BioPharma Inc.
16.2.4. TILT Biotherapeutics Ltd.
16.2.5. Oncorus, Inc.
16.2.6. Takara Bio Inc.
16.2.7. Vyriad
16.2.8. Transgene sa
16.2.9. Lokon Pharma AB
16.2.10. Pfizer Inc.
17. Oncolytic Virus Therapy Market Outlook
17.1. By Value (USD Million)
18. Oncolytic Virus Therapy Market Segmentation Analysis 2019-2028
18.1. By Therapy Type
18.1.1. HSV-Based Oncolytic Virus Therapy, 2019-2028F (USD Million)
18.1.2. Adenovirus-Based Oncolytic Virus Therapy, 2019-2028F (USD Million)
18.1.3. Reovirus
18.1.4. Poxviruses
18.1.5. NDV (Newcastle Disease Virus)
18.1.6. Others (Measles Virus; HVJ-E; SVV; Retrovirus; Parvovirus; Gamma-herpes Virus)
18.2. By Virus Type
18.2.1. Oncolytic Wild Type Viruses, 2019-2028F (USD Million)
18.2.2. Genetically Engineered Oncolytic Viruses, 2019-2028F (USD Million)
18.3. By Indication
18.3.1. Head & Neck Cancer, 2019-2028F (USD Million)
18.3.2. Lung Cancer, 2019-2028F (USD Million)
18.3.3. Kidney Cancer, 2019-2028F (USD Million)
18.3.4. Liver Cancer, 2019-2028F (USD Million)
18.3.5. Pancreatic Cancer, 2019-2028F (USD Million)
18.3.6. Breast Cancer, 2019-2028F (USD Million)
18.3.7. Colorectal Cancer, 2019-2028F (USD Million)
18.3.8. Sarcoma, 2019-2028F (USD Million)
18.3.8.1. Bone Cancer, 2019-2028F (USD Million)
18.3.8.2. Angiosarcoma, 2019-2028F (USD Million)
18.3.8.3. Fibrosarcoma, 2019-2028F (USD Million)
18.3.8.4. Leiomyosarcoma, 2019-2028F (USD Million)
18.3.8.5. Others, 2019-2028F (USD Million)
18.3.9. Melanoma, 2019-2028F (USD Million)
18.3.10. Others, 2019-2028F (USD Million)
18.4. By Demography
18.4.1. Pediatric, 2019-2028F (USD Million)
18.4.2. Adults, 2019-2028F (USD Million)
18.5. By End-User
18.5.1. Hospitals, 2019-2028F (USD Million)
18.5.2. Hospitals, 2019-2028F (USD Million)
18.5.3. Cancer Research Institutes, 2019-2028F (USD Million)
19. Oncolytic Virus Therapy Market, By Region, 2019-2028
19.1. North America, 2019-2028F (USD Million): U.S.
19.2. Europe, 2019-2028F (USD Million): Germany, U.K., France, Italy, Spain and Rest of Europe
19.3. Asia Pacific, 2019-2028F (USD Million): China, Japan, Australia and Rest of Asia-Pacific
19.4. Rest of World, 2019-2028F (USD Million)
20. Regional Oncolytic Virus Therapy Market Outlook (North America, Europe, Asia-Pacific and Rest of World)
20.1. Leading Companies in Oncolytic Virus Therapy Market
20.2. Assessment of macroeconomic factors
20.3. Analysis on the Development of Oncolytic Virus Therapies
For more information about this report visit https://www.researchandmarkets.com/r/5r62u0
